Natural Killer Cell Therapies Competitive Landscape Technology And Pipeline Analysis

" Natural Killer Cell Therapies - Competitive Landscape, Technology and Pipeline Analysis, 2018", report provides comprehensive Insight about pipeline drugs along with technologies involved across this Cell Therapy. The report provides the detailed analysis of 30+ products along with 20+ companies involved.

The report also covers a separate section for the Natural Killer Augmenters including Natural Killer Cell Activators and Natural Killer Enhancers. European Commission has granted Orphan Drug Designation to IPH4102 for the treatment of Cutaneous T-Cell Lymphoma.

Products covered by Phase

  • Phase II and Phase I
  • Pre-clinical

Overview of pipeline development activities for Natural Killer Cell Therapies

Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Natural Killer Cell Therapies

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Cell Therapy.


Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.


Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope

  • The report provides competitive pipeline landscape of Natural Killer Cell Therapies
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Natural Killer Cell Therapies
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Natural Killer Cell Therapies pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Natural Killer Cell Therapies and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from mid stage till preclinical stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to Buy

  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario across Natural Killer Cell Therapies to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Natural Killer Cell Therapies R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Natural Killer Cell Therapies pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Natural Killer Cell Therapies to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Natural Killer Cells Therapy Overview

Natural Killer (NK) Cells

Mechanism of Action of NK-cells

NK Cells in Cancer

NK Cell Therapies

Types of NK-based Immunotherapy

Natural Killer Cell Therapies

Natural Killer Cell Therapies and Targets

Targets and Number of Products

Collaborations& Licensing Agreements for NK Cells Therapy

Collaborations and Deal values

Licensing Agreement for Future Developments

Financing details of NK cell Therapies

Designation

Institutes involved in NK cell Therapies

Technologies for NK Cell Therapies

Pipeline Therapeutics for Natural Killer Cell Therapies

Therapeutics under Development by Companies

Mid Stage Products (Phase II)

Comparative Analysis

MG 4101: Green Cross Corporation

Product Description

Research and Development

Product Development Activities

(The list continues)

Early Stage Products (Phase I)

Comparative Analysis

Pre-clinical and Discovery Stage Products

Comparative Analysis

Therapeutic Assessment of Natural Killer Cell Therapies

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

NK Cells Based Prophylaxis

Cancer Breakthrough Program 2020

Natural Killer Cell Augmenters

Number of NK cell Augmenters by Targets

Collaborations for NK Cells Augmenters

Collaborations and Deal value

Licensing Agreement for future development of NK Cell Augmenters

Financing Details of NK Cells Augmenters

Grants Received by Companies for NK Cells Augmenters

Designation

Institutes involved in NK Cells Augmenters Based Therapies

Pipeline Therapeutics for Natural Killer Cells Augmenters

Therapeutics under Development by Companies

NK Cells Enhancers

NK Cells Activators

Natural Killer Cell Enhancers

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I)

Comparative Analysis

Pre –clinical Stage Products

Comparative Analysis

Natural Killer Cell Activators

Mid Stage Products (Phase II)

Comparative Analysis

Early Stage Products (Phase I and IND)

Comparative Analysis

Pre–clinical Stage Products

Comparative Analysis

Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)

Assessment by Monotherapy Products

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Market Drivers

Market Barriers

SWOT Analysis

Appendix

Table 1: Targets and Number of Products

Table 2: Collaboration and Deal Values

Table 3: Licensing Agreement for future development of NK Cell based Therapy

Table 4: Companies of NK cell based therapies financing for future developments

Table 5: Analysis of Natural Killer Cell Therapies On The Basis of Designation

Table 6: Institutes involved in NK Cell Therapies

Table 7:Companies and their Technologies for NK Cell Therapies

Table 8:Number of Products Under Development for Natural Killer Cell Therapies

Table 9: Number of Products under development by Companies

Table 10: Mid Stage Products (Phase II)

Table 11: Early Stage Products (Phase I)

Table 12: Pre-clinical and Discovery Stage Products

Table 13: Assessment by Monotherapy Products

Table 14: Assessment by Route of Administration

Table 15:Assessment by Stage and Route Of Administration

Table 16: Assessment by Molecule Type

Table 17: Assessment by Stage and Molecule Type

Table 18: Number of Products by Targets

Table 19: Collaboration and Deal Values for NK cell Augmenters

Table 20: Licensing Agreement for future development of NK Cell Augmenters Therapy

Table 21: Financing Details of NK Cells Augmenters

Table 22: Grants Received by Companies of NK Cells Augmenters

Table 23: Analysis of Natural Killer Cells Augmenters On The Basis of Designation

Table 24: Institutes involved in NK Cells Augmenters

Table 25: Technologies for NK Cell Augmenters

Table 26: Number of Products Under Development for Natural Killer Cells Augmenters

Table 27: Number of Products under development by Companies

Table 28: Number of Products under development by Companies

Table 29: Mid Stage Products (Phase II)

Table 30: Early Stage Products (Phase I)

Table 31: Pre-clinical Stage Products

Table 32: Mid Stage Products (Phase II)

Table 33: Early Stage Products (Phase I and IND)

Table 34: Assessment by Monotherapy Products

Table 35: Assessment by Route of Administration

Table 36: Assessment by Stage and Route of Administration

Table 37: Assessment by Molecule Type

Table 38: Assessment by Stage and Molecule Type

Figure 1: Mechanism of action

Figure 2: Analysis of Natural Killer Cell Therapies On The Basis of Designation

Figure 3: Number of Products under Development for Natural Killer Cell Therapies

Figure 4: Mid Stage Products (Phase II)

Figure 5: Early Stage Products (Phase I)

Figure 6: Pre-clinical and Discovery Stage Products

Figure 7: Assessment by Monotherapy Products

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: NK Cells Augmenters based therapies designation and Number of Products

Figure 13: Number of Products under Development for Natural Killer Cells Augmenters

Figure 14: Mid Stage Products (Phase II)

Figure 15: Early Stage Products (Phase I)

Figure 16: Pre-clinical Stage Products

Figure 17: Mid Stage Products (Phase II)

Figure 18: Early Stage Products (Phase I and IND)

Figure 19: Pre–clinical Stage Stage Products

Figure 20: Assessment by Monotherapy Products

Figure 21: Assessment by Route of Administration

Figure 22: Assessment by Stage and Route of Administration

Figure 23: Assessment by Molecule Type

Figure 24: Assessment by Stage and Molecule Type

Affimed

Altor Bioscience Corporation

AvidBiotic Corporation

Bristol-Myers Squibb

Celgene

CureTech

CytoVac

Dynavax

Fate Therapeutics

Five Prime Therapeutics

Fortress Biotech

GamidaCell

Glycostem Therapeutics

Green Cross Corporation

iCell Gene Therapeutics

Innate Pharma

Multimmune GmbH

NantKwest

Nohla Therapeutics

PersonGen BioTherapeutics (Suzhou)

Sorrento Therapeutics

Surface Oncology

ZIOPHARM Oncology

  • Tags:
  • Natural Killer Cell Therapies

Forward to Friend

Need A Quote